ABSTRACT
Background Major trauma results in dramatic changes in platelet behavior. Newly-formed platelets are more reactive than older platelets, but their contributions to hemostasis and thrombosis after severe injury have not been previously evaluated.
Objectives To determine the relationship between immature platelet metrics and circulating drivers of platelet production with clinical outcomes after major injury.
Methods Prospective observational cohort study of adult trauma patients. Platelet counts and the immature platelet fraction (IPF) were measured at admission, 24 hours, 72 hours and 7 days post-injury. Plasma proteins involved in thrombopoiesis were quantified at admission. The primary outcome was in-hospital mortality; secondary outcomes were venous thromboembolic events (VTE) and organ failure.
Results At two hours post-injury, immature platelet counts (IPC) were significantly lower in non-survivors (n=40) compared to survivors (n=236; 7.3x109/L vs 10.6x109/L, p=0.009). Similarly, impaired platelet function on thromboelastometry was associated with a lower admission IPC (9.1x109/L vs 11.9x109/L, p<0.001). However, at later timepoints we observed a significantly higher IPF and IPC in patients who developed VTE (21.0x109/L vs 11.1x109/L, p=0.02) and prolonged organ dysfunction (20.9 x109/L vs 11x109/L, p=0.003) compared to those who did not develop complications. Plasma levels of thrombopoietin at admission were significantly lower in in non-survivors (p<0.001), in patients with organ failure (p<0.001) and in those who developed VTE (p=0.04).
Conclusions Immature platelet depletion in the acute phase after major injury is associated with increased morality, whereas excessive immature platelet release at later timepoints may predispose to thrombosis and organ dysfunction.
ESSENTIALS
- Newly-formed platelets are highly active, but their role in outcomes after major trauma is unknown
- Immature platelets were quantified in a cohort of 276 severely injured patients
- Early depletion of immature platelets is associated with increased mortality and coagulopathy
- Raised immature platelet at later timepoints increases the risk of thrombosis and organ failure
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A.R. received a clinical research training fellowship (WT1390921) from the National Health Service Blood and Transplant (Bristol, UK). P.C.A., H.E.A. and T.D.W. received fundings from the British Heart Foundation. P.V. received fundings from the Academy of Medical Sciences and the National Institute for Health and Care Research. The Centre for Trauma Sciences receives support for rotational thromboelastometry reagents and equipment from Tem International GmbH (Munich, Germany).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ACIT-II study was approved on 13/11/2007 by London City + East Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS UK; +44 (0)207 104 8284; cityandeast.rec@hra.nhs.uk) REF: 07/Q0603/29
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Information: A.R. received a clinical research training fellowship (WT1390921) from the National Health Service Blood and Transplant (Bristol, UK). P.C.A., H.E.A. and T.D.W. received fundings from the British Heart Foundation. P.V. received fundings from the Academy of Medical Sciences and the National Institute for Health and Care Research. The Centre for Trauma Sciences receives support for rotational thromboelastometry reagents and equipment from Tem International GmbH (Munich, Germany).
Conflict of Interest: The authors declare that they have no conflicts of interest.
Presentations: Poster presentation at the XXX Congress of the International Society on Thrombosis and Hemostasis, London, UK, July 9-13, 2022.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos